论文信息 - Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. - 字舞流文

Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.

M. Castagneto | G. Tisone | M. Salizzoni | G. Gerunda | U. Valente | F. Filipponi | U. Cillo | A. Risaliti | A. Cavallari | D. Forti | L. Fassati

[1] P. Komolmit,et al. Tacrolimus in liver transplantation. , 1999, Expert opinion on investigational drugs.

[2] D. Samuel,et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. , 1998, Transplantation proceedings.

[3] P. Neuhaus,et al. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[4] L. Makowka,et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation: The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994;331:1110–1115 , 1995 .

[5] H. Bismuth. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. , 1995, Transplantation proceedings.

[6] S. Todo,et al. Current status of FK 506 in liver transplantation. , 1991, Transplantation proceedings.

[7] T. Starzl,et al. Liver, Kidney, and Thoracic Organ Transplantation Under FK 506 , 1990, Annals of surgery.